Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective observational study of serious adverse events after rituximab in non-rheumatoid autoimmune diseases
2008-006716-38Phase 3Active
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rituximab in autoimmune disease, collagenosis, vasculitis and 1 more, sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Additional safety endpoint. Started Mar 2009; status: active.
02
Drugs
rituximab
03
Conditions
autoimmune diseasecollagenosisvasculitisAntibody-mediated kidney allograft rejection (AMR)
Beyond the preview
Go deeper on 2008-006716-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006716-38.